NASDAQ$ESPR
Esperion Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Esperion reported its financial results for the first quarter ended March 31, 2025, with total revenue of $65.0 million and a net loss of $40.5 million.
Esperion reported a total revenue of $65.0 million for Q1 2025, a 53% decrease year-over-year, primarily due to a one-time milestone received in Q1 2024. Excluding this milestone, total revenue grew 63%. The company achieved a net loss of $40.5 million and a basic net loss per share of $0.21.
- Total revenue for Q1 2025 was $65.0 million, a 53% decrease year-over-year, but a 63% increase excluding a one-time milestone from Q1 2024.
- U.S. net product revenue grew 41% year-over-year to $34.9 million.
- The company surpassed one million retail prescription equivalents for its bempedoic acid products in the U.S.
- Bempedoic acid earned Level 1a recommendations in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes.
Headline financials
Revenue & EPS history
Esperion · Revenue · Quarterly
$65M
Revenue by segment
Esperion · $34M total across 2 segments · Q3 2023
- U.S. Net Product Revenue$20.3M+44.6%59.6%
- Collaboration Revenue$13.7M+173.5%40.4%
Forward guidance
Esperion expects full year 2025 operating expenses to be in the range of $215 million to $235 million, including approximately $15 million in non-cash expenses related to stock compensation.
Tailwinds
- The Company's partner in Japan, Otsuka Pharmaceutical Co., Ltd. is on track for expected approval and National Health Insurance pricing in the second half of 2025.
- Esperion's European partner Daiichi Sankyo Europe (DSE) continues to show strong revenue growth and market penetration.
- DSE received approval of NILEMDO for expanded cardiovascular risk reduction in Switzerland in Q1 2025.
- Neopharm Israel filed a New Drug Application for marketing approval of NEXLETOL and NEXLIZET in Q1 2025.
- The Company's previously filed New Drug Submissions to Health Canada for NEXLETOL and NEXLIZET are on track for review with an expected market approval in the fourth quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-2.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+0.9%
Avg return
30 days after
41%
18 / 44 earnings
Positive
+23.0%
Q3 2018
Best reaction
-47.6%
Q1 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -0.6% | — | |
| Q4 2025 | -11.5% | -19.7% | -28.3% | |
| Q3 2025 | -15.0% | +5.4% | +26.9% | |
| Q1 2025 | -7.7% | -23.8% | +10.5% | |
| Q4 2024 | +12.0% | +7.0% | -18.4% | |
| Q3 2024 | +3.2% | +10.0% | +57.5% | |
| Q2 2024 | -10.9% | -3.0% | -13.9% | |
| Q1 2024 | -3.8% | +3.3% | +16.5% | |
| Q4 2023 | -2.3% | -3.0% | +1.9% | |
| Q3 2023 | +3.7% | -5.2% | +64.6% | |
| Q2 2023 | +14.0% | +3.8% | +1.9% | |
| Q1 2023 | +8.1% | +14.1% | +0.0% | |
| Q4 2022 | -3.9% | +4.7% | -73.6% | |
| Q3 2022 | -1.1% | +5.3% | -14.6% | |
| Q2 2022 | +5.9% | +11.9% | +41.1% | |
| Q1 2022 | +11.3% | -3.8% | -1.9% | |
| Q4 2021 | +5.5% | +9.1% | +32.8% | |
| Q3 2021 | +5.3% | +2.3% | -11.3% | |
| Q2 2021 | -6.6% | -5.2% | -12.7% | |
| Q1 2021 | -25.1% | -16.5% | -20.7% | |
| Q4 2020 | -0.2% | -4.2% | -1.9% | |
| Q3 2020 | -19.3% | -15.7% | -0.8% | |
| Q2 2020 | -11.9% | -13.7% | -0.1% | |
| Q1 2020 | +8.8% | +19.1% | +11.9% | |
| Q4 2019 | -11.5% | -5.4% | -38.1% | |
| Q3 2019 | -8.0% | -5.2% | +22.4% | |
| Q2 2019 | -2.0% | -2.3% | -9.6% | |
| Q1 2019 | +5.0% | +0.3% | +2.5% | |
| Q4 2018 | +1.2% | +0.7% | -14.1% | |
| Q3 2018 | +23.0% | +29.4% | +17.0% | |
| Q2 2018 | +3.2% | +4.2% | +10.6% | |
| Q1 2018 | -47.6% | -41.8% | -46.1% | |
| Q4 2017 | +1.2% | +5.3% | -6.1% | |
| Q3 2017 | -1.9% | +0.0% | +12.7% | |
| Q2 2017 | +11.9% | +9.2% | +10.4% | |
| Q3 2016 | -2.5% | -3.9% | +8.8% | |
| Q2 2016 | -1.0% | -2.2% | -4.2% | |
| Q1 2016 | -7.8% | — | — | |
| Q4 2015 | -3.4% | — | — | |
| Q3 2015 | -3.3% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2015 | +2.6% | — | — | |
| Q4 2014 | +1.6% | — | — | |
| Q3 2013 | -3.3% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro